Baraclude - After Plavix, Baraclude is the next significant challenge that BMS will have to face immediately.
FORBES: Looking At Bristol-Myers Squibb's Major Patent Expiries That Will Drag On Growth
Baraclude is approved in the United States to treat patients with chronic hepatitis B in adults who have active virus and liver damage.
FORBES: Bristol-Myers Squibb Hit With Surprise Patent Loss
Entecavir is the active ingredient in Baraclude.
应用推荐
模块上移
模块下移
不移动